10-Q: NAII Reports Q2 Loss Amid Sales Growth, Covenant Breach

Natural Alternatives International, Inc. reported increased net sales for the second quarter and first half of fiscal 2026, despite incurring net losses and non-compliance with debt covenants.

Summary

• Net sales for the three months ended December 31, 2025, increased 2% to $34.795 million, compared to $34.078 million in the prior year.
• Net sales for the six months ended December 31, 2025, increased 8% to $72.525 million, compared to $67.228 million in the prior year.
• The company reported a net loss of $(2.553) million for the three months ended December 31, 2025, an increase from $(2.191) million in the prior year.
• Net loss for the six months ended December 31, 2025, was $(2.844) million, an improvement from $(4.173) million in the prior year.
• Gross profit significantly improved, increasing 49% to $2.491 million for the three months and 75% to $6.888 million for the six months ended December 31, 2025.
• Gross profit margin rose to 7.2% for the three months and 9.5% for the six months ended December 31, 2025, primarily due to increased sales volume, improved factory utilization, and a favorable product sales mix.
• Private-label contract manufacturing sales increased 9% for the six months ended December 31, 2025, driven by existing and new customer orders.
• Patent and trademark licensing revenue decreased 15% to $3.656 million for the six months ended December 31, 2025, primarily due to lower instant release CarnoSyn raw material sales and decreased royalty income, partially offset by sales of the new TriBsyn product.
• The company experienced a loss from operations, primarily attributed to underutilization of factory capacities.
• Management now anticipates a net loss for the second half of fiscal 2026 and for the full fiscal 2026 year, citing declines in customer forecasted sales and delayed new product launches.
• The company was not in compliance with maximum net loss and fixed charge coverage ratio covenants of its credit agreement as of December 31, 2025, and expects continued non-compliance for the third quarter of fiscal 2026.
• A waiver was received from Wells Fargo for covenant violations for the three months ended September 30, 2025, and discussions are ongoing for additional waivers and a potential new asset-based lending facility.
• A tentative settlement agreement for a maximum of $1.25 million was reached in a class action lawsuit brought by former employees, with court approval estimated to take three to six months.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a concerning report due to the projected full-year net loss, ongoing debt covenant non-compliance, and significant cash burn from operations, despite some positive sales and gross margin trends.

Positives

• Net sales increased by 2% for the three months and 8% for the six months ended December 31, 2025, compared to the prior year periods.
• Gross profit saw substantial improvement, rising 49% for the three months and 75% for the six months ended December 31, 2025.
• Gross profit margin increased to 7.2% for the three months and 9.5% for the six months ended December 31, 2025, driven by higher sales volume, better factory utilization, and a favorable product mix.
• Private-label contract manufacturing sales grew 9% for the six months ended December 31, 2025, due to increased orders from existing customers and new customer shipments.
• Selling, general and administrative expenses decreased slightly by 2% for the three months and 1% for the six months ended December 31, 2025, primarily from reduced credit loss allowances and lower patent-related legal fees.
• The new TriBsyn product, a patent-pending carnosine booster, was launched in August 2024, targeting the Wellness and Healthy Aging markets with improved bioavailability and absorption.
• Received a waiver from Wells Fargo for debt covenant violations for the three months ended September 30, 2025.
• Management is in active discussions with Wells Fargo for additional waivers and with a potential new asset-based lender for an increased borrowing facility to support growth and provide flexibility.

Negatives

• Net loss increased to $(2.553) million for the three months ended December 31, 2025, compared to $(2.191) million in the prior year.
• A net loss is now projected for the second half of fiscal 2026 and the full fiscal 2026 year, attributed to declines in customer forecasted sales and delayed new product launches.
• Loss from operations for both the three-month ($(1.847) million) and six-month ($(1.563) million) periods, primarily due to underutilization of factory capacities.
• Patent and trademark licensing revenue decreased 15% for the six months ended December 31, 2025, due to lower raw material sales and royalty income.
• The company is not in compliance with maximum net loss and fixed charge coverage ratio covenants of its credit agreement as of December 31, 2025, and anticipates non-compliance for the third quarter of fiscal 2026.
• Cash and cash equivalents significantly decreased from $12.325 million at June 30, 2025, to $3.753 million at December 31, 2025.
• Net cash used in operating activities increased substantially to $10.353 million for the six months ended December 31, 2025, compared to $3.406 million in the prior year, mainly due to changes in accounts receivable and inventories.
• Other expense, net, increased significantly due to higher foreign currency exchange losses.
• The provision for income taxes shifted to an expense of $0.2 million for the three months and $0.3 million for the six months ended December 31, 2025, partly due to a 5% Swiss withholding tax on a dividend and a full valuation allowance on domestic net deferred tax assets.
• The maximum principal amount available under the credit facility with Wells Fargo was decreased from $12.5 million to $10.0 million.

Risks

• Ability to develop market acceptance and increase sales of new products, and maintain or improve existing customer relationships.
• Future financial and operating results, including projections of net sales, revenue, income or loss, profit margins, expenditures, and liquidity.
• Sufficiency of available cash and cash equivalents, including continued access to borrowing under credit facilities.
• Inventory levels, adequacy of quality raw material, and ability to maintain inventory to meet future customer demand.
• Sources, availability, and quality of raw materials, including the limited number of suppliers for beta-alanine.
• Ability to price products to achieve profit margin targets in a volatile raw material environment and potential for new tariffs.
• Ability to maintain or increase patent and trademark licensing revenues.
• Ability to improve operating efficiencies, manage costs and business risks, and improve or maintain profitability.
• Ability to protect intellectual property.
• Impact of future economic and political conditions, and currency exchange rates on results of operations.
• Outcome of litigation, regulatory, and tax matters, and associated costs.
• Potential manufacturing and distribution channels, product returns, and product recalls.
• Impact of external factors on business and results of operations, such as seasonal variations in net sales.
• Ability to operate within FDA Good Manufacturing Practices (GMPs) standards.
• Adequacy of financial reserves and allowances.
• Impact of accounting pronouncements and their adoption.
• Customer concentration risk, where the loss of any major customer or significant decline in sales could materially impact net sales and operating results (Customer 1 accounted for 31% of H1 FY26 net sales).
• Supplier concentration risk, where the loss of any key raw material supplier could materially impact net sales and results of operations (Supplier 1 accounted for $4.444 million of purchases in H1 FY26).
• Geopolitical uncertainty, including conflicts in Ukraine, Gaza, Lebanon, Iran, Syria, and Sudan, which could affect raw material sourcing (e.g., from Israel), consumer behavior, shipping expenses, and foreign exchange/interest rates.
• Government trade tariffs, which could increase product costs, impact beta-alanine availability, and reduce demand for products.
• Inability to successfully complete the negotiation of a new credit facility or obtain additional waivers for covenant non-compliance.
• Uncertainty regarding the IRS's denial of the Employee Retention Tax Credit for Q3 2021, which could result in a loss of approximately $0.6 million.

Future Outlook

Management anticipates increasing sales revenue during the remaining two quarters of fiscal 2026 compared to prior year periods and the first half of this year. However, a net loss is now projected for the second half of fiscal 2026 and for the full fiscal 2026 year, primarily due to declines in customer forecasted sales and delayed new product launches. The company believes its available cash, cash equivalents, potential cash flows from operations, and line of credit will be sufficient to fund current working capital needs and capital expenditures through at least the next 12 months. The company is also assessing the impact of recently issued accounting pronouncements (ASU 2025-12, ASU 2025-11, ASU 2025-09) on its financial statements and disclosures.

Management Comments

• "We believe SR CarnoSyn may provide a unique opportunity within the growing Wellness and Healthy Aging markets but acceptance of this product offering has been limited as we only offer this product in tablet form."
• "We believe TriBsyn and its patent-pending formulation will allow us to better penetrate the Wellness and Healthy Aging channel."
• "The elimination of paresthesia while maintaining efficacy of dosage creates a new opportunity to reach segments of the market that to date have been untapped, including older adults, vegetarians, and vegans."
• "We believe our efforts to refine our formulations and product offerings will be positively received and result in significant opportunity for increased sales of our patented products."
• "We are also working on several additional innovations we believe could lead to new patentable products for CarnoSyn Brands in the future."
• "Although we anticipate we will increase our sales revenue during the remaining two quarters of fiscal 2026 as compared to the prior year periods and the first half of this year, we now believe that we will experience a net loss in the second half of fiscal 2026, and a net loss for the full fiscal 2026 year due to declines in our customers forecasted sales along with delayed new product launches."
• "Overall, we believe our available cash, cash equivalents, potential cash flows from operations, and our line of credit will be sufficient to fund our current working capital needs and capital expenditures through at least the next 12 months."
• "We are in discussions with the lender regarding an additional waiver for these events of non-compliance, and they have indicated they will not exercise their option to terminate the agreement."
• "Concurrently, we are in active discussions with a potential new asset-based lender we believe may provide an increased borrowing facility to support our expected business growth and provide greater flexibility in working capital availability and covenant requirements."

Industry Context

StockSavvy.ai notes that Natural Alternatives International operates in the competitive nutritional supplements and health care products industry, focusing on private-label contract manufacturing and proprietary ingredients. The company's strategic emphasis on developing new products like TriBsyn for the Wellness and Healthy Aging markets reflects a broader industry trend towards specialized, science-backed formulations targeting specific consumer demographics. However, challenges such as factory underutilization and declines in customer forecasted sales suggest potential industry-wide headwinds or increased competitive pressures impacting demand for contract manufacturing services. The ongoing investment in R&D for CarnoSyn product offerings and patent protection is crucial for maintaining a competitive edge in an innovation-driven sector.

Corporate Governance

Legal Proceedings

• Sued by three former employees in December 2023 in two separate, substantially identical matters filed as a putative class action and a California Private Attorney General Act action, seeking awards for similarly situated employees going back ten years or more.
• A tentative settlement agreement was reached on July 3, 2025, for a maximum contribution of $1.25 million, plus estimated legal fees of $150,000 initially and an additional $12,000 accrued during the three months ended December 31, 2025.
• The court has consolidated the two actions, and the process of obtaining court approval for the settlement is estimated to take approximately another three to six months.
• The IRS sent a 105c letter on December 9, 2024, denying the Employee Retention Tax Credit for the third quarter of calendar 2021 (approximately $0.6 million), which the company is contesting.

Stakeholder Impact

• Shareholders face potential dilution from the increased share reserve under the amended 2020 Omnibus Stock Incentive Plan and risk of share price decline due to projected net losses and debt covenant non-compliance.
• Employees are impacted by the settlement of former employee lawsuits and continue to benefit from stock-based compensation plans.
• Customers in the private-label contract manufacturing segment benefit from increased sales and new product offerings like TriBsyn, but may face increased product costs due to potential trade tariffs.
• Suppliers, particularly those providing beta-alanine, are critical, and the company's dependency on a limited number of these suppliers poses a risk to operations.
• Creditors, specifically Wells Fargo, are impacted by the company's non-compliance with debt covenants, requiring waivers and discussions for a new credit facility, indicating increased credit risk.

Next Steps

• Continue sales and marketing activities to promote CarnoSyn, SR CarnoSyn, and TriBsyn beta-alanine products on multiple platforms.
• Leverage state-of-the-art, certified facilities to increase value for private-label contract manufacturing customers and develop relationships with additional quality-oriented customers.
• Expand commercialization of the beta-alanine patent estate through raw material sales, developing distribution channels in Sports Nutrition, Wellness and Healthy Aging, and Medical foods for SR CarnoSyn and TriBsyn.
• Exploit new contract manufacturing opportunities, license and royalty agreements, and protect proprietary rights.
• Improve operational efficiencies and manage costs and business risks to enhance profitability.
• Continue discussions with Wells Fargo for additional waivers regarding covenant non-compliance for Q2 and Q3 fiscal 2026.
• Negotiate with a potential new asset-based lender for an increased borrowing facility.
• Complete the court approval process for the former employee class action settlement, estimated to take another three to six months.
• Await further correspondence from the IRS regarding the appeal of the Q3 2021 Employee Retention Tax Credit denial.
• Plan to adopt ASU 2025-12 and ASU 2025-09 for interim periods within the fiscal year beginning July 1, 2027.
• Plan to adopt ASU 2025-11 for interim periods within the fiscal year beginning July 1, 2028.

Key Dates

Recommendation

While Natural Alternatives International, Inc. demonstrated positive trends in net sales growth and gross profit margin improvement, the projected full-year net loss, ongoing debt covenant non-compliance, and significant cash utilization from operating activities present substantial financial risks. The company's active discussions for a new credit facility and waivers from its current lender introduce a degree of uncertainty. A 'Hold' recommendation is warranted as investors should closely monitor the resolution of these financial challenges and the company's ability to return to sustained profitability before making further investment decisions.

Keywords

Nutritional supplements, Contract manufacturing, Beta-alanine, CarnoSyn, SR CarnoSyn, TriBsyn, SEC filing, 10-Q, Financial results, Debt covenants, Liquidity, Patent licensing, Wellness, Healthy Aging, Risk factors, Geopolitical uncertainty, Trade tariffs